Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J8ID
|
||||
| Former ID |
DCL000672
|
||||
| Drug Name |
5-HT4/D2 antagonists
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Terminated | [1] | ||
| Company |
Johnson & Johnson
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 4 receptor | Target Info | Antagonist | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT4 type receptor mediated signaling pathway | |||||
| PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.